Tag: RE-DUAL PCI

Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of Pradaxa® (dabigatran etexilate)

NGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it will present nine sub-analyses from the RE-DUAL PCITM trial and GLORIATM-AF Registry Program at the upcoming ESC Congress 2018, organised by the European Society of Cardiology, taking place in Munich, Germany on the 25-29 […]